HitGen Collaborates with Kymera to Identify Protein Degradation Targets

23:24 EST 15 Jan 2020 | ChinaBio Today

HitGen, a Chengdu drug discovery company, will collaborate with Kymera Therapeutics of Cambridge, MA to identify small molecule leads for Kymera targets. Kymera is developing drug candidates that cause protein degradation to treat disease. Its goal is use the body’s innate protein recycling machinery to degrade dysregulated, disease-causing proteins. HitGen will apply its DNA-encoded libraries (DEL) to discover compounds that bind to Kymera targets. Kymera will own the rights to the compounds. HitGen will receive an undisclosed upfront payment from Kymera and be eligible for milestone payments. More details....

Share this with colleagues:

Original Article: HitGen Collaborates with Kymera to Identify Protein Degradation Targets


More From BioPortfolio on "HitGen Collaborates with Kymera to Identify Protein Degradation Targets"

Quick Search

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...